Project: IMAGINe – High Risk High Gain IMAGINe (France)

About

Targeting intratumor metabolic heterogeneity in neuroblastoma to develop innovative treatments (IMAGINe)

Kind: National.
Duration: 2024–2029 (48 months).
Partners & funding amounts: CRCM (Marion Legrand, Eddy Pasquier), CRCL (Marie-Laure Broutier); amount for team: 120 k€.
Responsibilities: Co-PI.
Theme & content of work: Deploys Infinity-SCENITH to screen metabolic inhibitors across neuroblastoma identities and link metabolic states to epigenetic programs and chemosensitivity for precision combinations.
Scope & impact: Preclinical prioritization of metabolism-guided combinations in patient-derived organoids with a pipeline to clinical translation.

JOB: Interested? Looking for an engineer for this project